<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312436853</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312436853</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cerebral blood flow abnormalities in neurologically asymptomatic patients with primary antiphospholipid syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Medina</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">1</xref>
<xref ref-type="aff" rid="aff1-0961203312436853">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Molina-Carrión</surname><given-names>LE</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Angeles-Garay</surname><given-names>U</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vera-Lastra</surname><given-names>O</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">2</xref>
<xref ref-type="aff" rid="aff1-0961203312436853">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Arias-Flores</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Romero-Sánchez</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jara</surname><given-names>LJ</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436853">2</xref>
<xref ref-type="aff" rid="aff1-0961203312436853">6</xref>
<xref ref-type="corresp" rid="corresp1-0961203312436853"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312436853"><sup>1</sup>Clinical Research Unit, Hospital de Especialidades Centro Médico La Raza, IMSS,Mexico City, Mexico; <sup>2</sup>Universidad Nacional Autónoma de México, Mexico City, Mexico; <sup>3</sup>Neurology Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico; <sup>4</sup>Epidemiology Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico; <sup>5</sup>Internal Medicine Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico; and <sup>6</sup>Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS,Mexico City, Mexico</aff>
<author-notes>
<corresp id="corresp1-0961203312436853">Luis J Jara, Hospital de Especialidades Centro Médico la Raza, Seris y Zaachila S/N Col. La Raza, CP.02990 Mexico City, Mexico Email: <email>luis_jara_quezada@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>642</fpage>
<lpage>648</lpage>
<history>
<date date-type="received"><day>3</day><month>1</month><year>2011</year></date>
<date date-type="accepted"><day>3</day><month>1</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> To evaluate cerebral blood flow abnormalities in primary antiphospholipid syndrome (PAPS) patients without ongoing neurological manifestations. <bold>Patients and methods:</bold> We included 28 PAPS patients and 28 healthy controls. Carotid Doppler ultrasound, and echocardiographic evaluation were done. Transcranial Doppler ultrasonography measured mean flow velocity (MFV) in the carotid siphon, middle, anterior, posterior, intracranial vertebral arteries, and basilar artery (11 cerebral arteries). Results were considered abnormal when the MFV was out of the normal range according to age and/or flow asymmetry and/or more than four arterial segments affected. <bold>Results:</bold> The mean age of patients was 41.4 ± 11.2 and 39.3 ± 8.6 years in controls. Disease duration was 11 ± 2.7 years. A significant increase in MFV in 7/11 cerebral arteries in PAPS patients, mainly in the middle and anterior cerebral arteries was found compared with controls. A significant association between lupus anticoagulant, history of stroke and obesity with a greater number of affected arteries was found. We did not find an association between MFV and abnormal echocardiography, arterial hypertension and carotid intima-media thickness. <bold>Conclusions:</bold> Asymptomatic patients with PAPS can have significantly increased MFVs. These alterations may be the consequence of accelerated atherosclerosis, PAPS vasculopathy or both. Whatever the cause, these findings can represent a risk for stroke in PAPS patients that needs the trial of other therapeutic options.</p>
</abstract>
<kwd-group>
<kwd>Cerebral blood flow</kwd>
<kwd>primary antiphospholipid syndrome</kwd>
<kwd>transcranial doppler</kwd>
<kwd>vasculopathy</kwd>
<kwd>atherosclerosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312436853" sec-type="intro"><title>Introduction</title>
<p>Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis and/or pregnancy morbidity with positive antiphospholipid antibodies (aPL) that include lupus anticoagulant (LA), anticardiolipin (aCL) antibodies, and/or anti-beta 2-glycoprotein 1 (anti-β2GP1) antibodies.<sup><xref ref-type="bibr" rid="bibr1-0961203312436853">1</xref></sup> Central nervous system (CNS) involvement is one of the most important targets in PAPS and associated APS characterized by arterial and venous thrombosis, and non-thrombotic neurological syndromes such as psychiatric features, seizures, chorea, multiple sclerosis, cognitive dysfunction, and so on.<sup><xref ref-type="bibr" rid="bibr2-0961203312436853">2</xref></sup> The majority of CNS manifestations are caused by obliteration of small or medium-sized cerebral arteries known as APS ‘vasculopathy’.<sup><xref ref-type="bibr" rid="bibr3-0961203312436853">3</xref></sup> Most lesions in cerebral vasculopathy are noninflammatory and are characterized by reactive endothelial hyperplasia with or without thrombosis of small arterioles.<sup><xref ref-type="bibr" rid="bibr4-0961203312436853">4</xref></sup> Therefore, abnormalities in cerebral blood flow (CBF) could be a reflection of endothelial lesions.</p>
<p>Different methods have been employed to evaluate CBF in APS patients such as single photon emission computerized tomography, magnetic resonance imaging and positron emission tomography.<sup><xref ref-type="bibr" rid="bibr5-0961203312436853">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203312436853">6</xref></sup> Transcranial Doppler (TCD), a non-invasive technique that measures CBF and cerebral microembolic signals, demonstrated that patients with PAPS and associated SLE had a decrease in the total cerebral circulation with asymmetry of arterial blood flow. Cerebral microembolism was detected in APS patients with a history of cerebral ischemia and active SLE.<sup><xref ref-type="bibr" rid="bibr7-0961203312436853">7</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr9-0961203312436853">9</xref></sup> However, CBF changes in PAPS without CNS manifestations have not been studied. Therefore, the aim of the present study was to investigate CBF abnormalities in PAPS patients without ongoing neurological manifestations.</p></sec>
<sec id="sec2-0961203312436853" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203312436853" sec-type="subjects"><title>Patients</title>
<p>A total of 28 PAPS patients meeting the updated Sapporo Criteria,<sup><xref ref-type="bibr" rid="bibr10-0961203312436853">10</xref></sup> from the APS outpatient clinic of the Rheumatology Department, Hospital de Especialidades ‘Dr. Antonio Fraga Mouret’ Centro Médico La Raza, without ongoing neurological manifestations, were enrolled in a cross-sectional study. Informed consent was obtained prior to enrollment. Clinical data from patients' charts included information of type of thrombosis, traditional cardiovascular risk factors, history of central nervous system involvement, including cerebrovascular ischemia and migraine, carotid Doppler ultrasound (CDU), cardiac evaluation by echocardiography and immunological profile, including anticardiolipin antibodies (aCL) IgG or IgM isotype, IgG anti-β2GP1 or lupus anticoagulant (LA). At the time of TCD, PAPS patients and controls did not have ongoing neurological manifestations, including manifestations such as migraine. All patients were under oral anticoagulant treatment, and they were matched by age and gender with a control group without clinical evidence of disease and antecedents of cardiac, peripheral or cerebrovascular diseases, recruited from hospital employees.</p></sec>
<sec id="sec4-0961203312436853"><title>Transcranial Doppler</title>
<p>We performed TCD through orbitary, transtemporal and occipital windows with evaluation of the intracranial circulation using a trans-scan 3D Doppler (Siemens) in patients and controls. The method utilized a 2 MHz pulse wave transducer. A complete study included insonation of the middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), carotid siphon (CS), intracranial vertebral arteries, (VA), and basilar artery (BA). The insonation depth was 40–66 mm for anterior circulation, and from 60 to 90 mm for posterior circulation. It was performed by an expert neurologist (LE M-C) twice in each artery, with measurements in patients and controls of peak systolic flow velocities and mean flow velocities (MFV) in cm/s. Measurement of at least four arteries per patient was required for the study inclusion. Abnormal TCD was considered if MFV were out of the normal range according to age and/or flow asymmetry (&gt;20% difference between left and right MFV) and/or more than four arterial segments affected. Normal values according to age and arterial segment<sup><xref ref-type="bibr" rid="bibr11-0961203312436853">11</xref></sup> are shown in <xref ref-type="table" rid="table1-0961203312436853">Table 1</xref>.
<table-wrap id="table1-0961203312436853" position="float"><label>Table 1</label><caption><p>Mean flow velocity normal values in the cranial arteries according to age. Velocities are expressed as mean ± SD (cm/s)</p></caption>
<graphic alternate-form-of="table1-0961203312436853" xlink:href="10.1177_0961203312436853-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Age (yrs)</th>
<th>Middle cerebral artery</th>
<th>Anterior cerebral artery</th>
<th>Posterior cerebral artery</th>
<th>Basilar artery</th>
<th>Vertebral artery</th></tr></thead>
<tbody align="left">
<tr>
<td>10–29</td>
<td>70 ± 16.4</td>
<td>61 ± 14.7</td>
<td>55 ± 9</td>
<td>46 ± 11</td>
<td>45 ± 9.8</td></tr>
<tr>
<td>30–49</td>
<td>57 ± 11.2</td>
<td>48 ± 7.1</td>
<td>42 ± 8.9</td>
<td>38 ± 8.6</td>
<td>35 ± 8.2</td></tr>
<tr>
<td>50–59</td>
<td>51 ± 9.7</td>
<td>46 ± 9.4</td>
<td>39 ± 9.9</td>
<td>32 ± 7</td>
<td>37 ± 10</td></tr>
<tr>
<td>60–70</td>
<td>41 ± 7</td>
<td>38 ± 5.6</td>
<td>36 ± 7.9</td>
<td>32 ± 6.7</td>
<td>35 ± 7</td></tr>
</tbody>
</table>
</table-wrap></p>
<p>Pulsatility Index (PI) is a comparison of systolic flow to diastolic flow, and the values reflect low resistance (e.g. brain vessels) or high resistance (e.g. the extremities and face). The normal value for the cerebral arteries varies from 0.5 to 1.19.<sup><xref ref-type="bibr" rid="bibr12-0961203312436853">12</xref></sup> Normal values of PI ranged from 0.5 to 1 adjusted to our equipment. PI lower than 0.5 suggest a proximal narrowing/occlusion or an arteriovenous malformation, while a PI greater than this value may be caused by a distal occlusion, arterial constriction or high intracranial pressure.</p></sec>
<sec id="sec5-0961203312436853"><title>Statistical analysis</title>
<p>We employed the statistical package SPSS v.17.0 for Windows. Descriptive statistics for demographic variables were used. Fisher’s exact test was applied for categorical variables. MFV between patients and controls was analyzed by Student’s <italic>t</italic>-test. A Chi-square test for linear trend with CI 95% was calculated. A logistic regression model was used to evaluate the association between cardiovascular risk factors and the number of cerebral arteries affected; <italic>p</italic> &lt; 0.05 was taken as statistically significant.</p></sec></sec>
<sec id="sec6-0961203312436853" sec-type="results"><title>Results</title>
<p>Out of 28 PAPS patients studied, 17 (60.7%) were female and 11 (39.3%) were male. The mean age was 41.4 ± 11.2 (range 20–60 years). Mean duration of the illness was 11 ± 2.7 (range 6–16 years). The mean age of the 28 controls was 39.3 ± 8.6 (range 21–54 years) (<italic>p</italic> = 0.42). The majority of patients had venous thrombosis as a PAPS manifestation 19/28 (33.9%), arterial thrombosis in 5/28 (8.9%), and arterial plus venous thrombosis in 4/28, (7.1%), deep venous thrombosis was the most frequent manifestation. We did not find an association with a specific manifestation and abnormal TCD. The mean international normalized ratio (INR) was 2.5–3. Cardiovascular risk factors are described in <xref ref-type="table" rid="table2-0961203312436853">Table 2</xref>. An increase of MFV in the cerebral arteries of PAPS patients compared with healthy controls was found. This increase was significant in the right MCA, right and left ACA, and right PCA. The odds ratios show the risk of having higher cerebral blood flow in PAPS patients in comparison with the controls (<xref ref-type="table" rid="table3-0961203312436853">Table 3</xref>). Comparison of CBF between patients and controls is shown in <xref ref-type="table" rid="table4-0961203312436853">Table 4</xref>. Arterial hypertension was present in six patients and they were treated with enalapril. An analysis of this subset did not show differences in MFV or number of affected arteries (data not shown). Only five PAPS patients had a history of a cerebrovascular event (four strokes and one transient ischemic attack (TIA)), and two of them had hemiparesis as sequela. Further examination of this subgroup revealed an association between history of stroke and a major number of affected arteries but without any other differences in CBF with the remaining patients. In the four PAPS patients with migraine history we did not find differences in CBF compared with those without a migraine history. A minority of patients presented low cerebral blood flow. There were differences in mean PI between cases and controls in the left PCA (1.15 ± 0.36 vs. 1.00 <italic>p</italic> = 0.04) and BA (0.85 ± 0.23 vs. 0.70 ± 0.10 <italic>p</italic> = 0.01). There was no variability related to flow asymmetry in the total amount of affected arteries in either group (5.3 ± 2.6 vs. 4.2 ± 2.3 arteries). We did not find correlation between carotid intima media thickness (IMT) and number of affected arteries (<italic>R</italic> = 0.04, <italic>p</italic> = 0.78). An association between the presence of LA and abnormal TCD defined as more than four arterial segments affected was found (10/12 (83.3%) vs. 2/12 (16.7%), <italic>p</italic> = 0.032). We did not find any association between aCL IgG, IgM, and IgG anti-β2GP1 with abnormal TCD. Transthoracic echocardiography was performed in 17/28 patients (60.7%), 13 were normal, 4 had valvulopathy and 3 patients had pulmonary hypertension without hemodynamic repercussions. There was no association between the total number of affected arteries and abnormal echocardiography. Logistic regression analysis for cardiovascular risk factors demonstrated an association between history of stroke, obesity and age (range 35–44 years) with a greater number of affected arteries (more than four arteries with abnormal MFV) (<italic>p</italic> &lt;0.05).
<table-wrap id="table2-0961203312436853" position="float"><label>Table 2</label><caption><p>Cardiovascular risk factors in patients and controls</p></caption>
<graphic alternate-form-of="table2-0961203312436853" xlink:href="10.1177_0961203312436853-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Risk factors</th>
<th>Patients (<italic>n</italic> = 28)</th>
<th>Controls (<italic>n</italic> = 28)</th>
<th><italic>p</italic> value</th></tr></thead>
<tbody align="left">
<tr>
<td>Age</td>
<td>41.4 ± 11.2</td>
<td>39.3 ± 8.6</td>
<td>0.3</td></tr>
<tr>
<td>Arterial hypertension</td>
<td>6</td>
<td>1</td>
<td>0.1</td></tr>
<tr>
<td>Diabetes mellitus</td>
<td>0</td>
<td>0</td>
<td>0</td></tr>
<tr>
<td>Dyslipidemia</td>
<td>8</td>
<td>2</td>
<td>0.07</td></tr>
<tr>
<td>Smoking</td>
<td>3</td>
<td>4</td>
<td>1</td></tr>
<tr>
<td>Overweight</td>
<td>10</td>
<td>1</td>
<td>0.005</td></tr>
<tr>
<td>Obesity</td>
<td>5</td>
<td>3</td>
<td>0.7</td></tr>
<tr>
<td>Stroke</td>
<td>4</td>
<td>0</td>
<td>0.11</td></tr>
<tr>
<td>TIA</td>
<td>1</td>
<td>0</td>
<td>1</td></tr>
<tr>
<td>Migraine</td>
<td>4</td>
<td>0</td>
<td>0.11</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312436853"><p>TIA: transient ischemic attack.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0961203312436853" position="float"><label>Table 3</label><caption><p>Comparison of flow abnormalities in cerebral arteries in PAPS patients and controls</p></caption>
<graphic alternate-form-of="table3-0961203312436853" xlink:href="10.1177_0961203312436853-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Artery</th>
<th>Cases</th>
<th>Controls</th>
<th>OR</th>
<th>IC</th>
<th><italic>p</italic><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></th></tr></thead>
<tbody align="left">
<tr>
<td>Right carotid siphon</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>1</td>
<td>2</td>
<td/>
<td/>
<td>0.207</td></tr>
<tr>
<td> • Normal</td>
<td>15</td>
<td>21</td>
<td>1.4286</td>
<td>0.118–17.234</td>
<td/></tr>
<tr>
<td> • High</td>
<td>8</td>
<td>5</td>
<td>3.2</td>
<td>0.226–45.191</td>
<td/></tr>
<tr>
<td>Left carotid siphon</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>2</td>
<td>1</td>
<td/>
<td/>
<td>0.133</td></tr>
<tr>
<td> • Normal</td>
<td>11</td>
<td>22</td>
<td>0.25</td>
<td>0.02–3.067</td>
<td/></tr>
<tr>
<td> • High</td>
<td>11</td>
<td>5</td>
<td>1.1</td>
<td>0.08–15.153</td>
<td/></tr>
<tr>
<td>Right middle cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>0</td>
<td>8</td>
<td/>
<td/>
<td><bold>0.001</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>14</td>
<td>16</td>
<td/>
<td/>
<td/></tr>
<tr>
<td> • High</td>
<td>13</td>
<td>4</td>
<td/>
<td/>
<td/></tr>
<tr>
<td>Left middle cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>0</td>
<td>1</td>
<td/>
<td/>
<td>0.409</td></tr>
<tr>
<td> • Normal</td>
<td>19</td>
<td>20</td>
<td/>
<td/>
<td/></tr>
<tr>
<td> • High</td>
<td>9</td>
<td>7</td>
<td/>
<td/>
<td/></tr>
<tr>
<td>Right anterior cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>5</td>
<td>8</td>
<td/>
<td/>
<td><bold>0.034</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>8</td>
<td>14</td>
<td>0.914</td>
<td>0.222–3.765</td>
<td/></tr>
<tr>
<td> • High</td>
<td>14</td>
<td>5</td>
<td>4.48</td>
<td>0.986–20.354</td>
<td/></tr>
<tr>
<td>Left anterior cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>4</td>
<td>7</td>
<td/>
<td/>
<td><bold>0.038</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>10</td>
<td>16</td>
<td>1.094</td>
<td>0.254–4.712</td>
<td/></tr>
<tr>
<td> • High</td>
<td>13</td>
<td>5</td>
<td>4.55</td>
<td>.915–22.627</td>
<td/></tr>
<tr>
<td>Right posterior cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>2</td>
<td>15</td>
<td/>
<td/>
<td><bold>0.000</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>17</td>
<td>12</td>
<td>10.62</td>
<td>2.04–55.331</td>
<td/></tr>
<tr>
<td> • High</td>
<td>8</td>
<td>1</td>
<td>60</td>
<td>4.689–767.819</td>
<td/></tr>
<tr>
<td>Left posterior cerebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>2</td>
<td>4</td>
<td/>
<td/>
<td>0.088</td></tr>
<tr>
<td> • Normal</td>
<td>17</td>
<td>20</td>
<td>1.7</td>
<td>0.277–10.454</td>
<td/></tr>
<tr>
<td> • High</td>
<td>8</td>
<td>3</td>
<td>5.333</td>
<td>0.619–45.991</td>
<td/></tr>
<tr>
<td>Right vertebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>2</td>
<td>9</td>
<td/>
<td/>
<td><bold>0.000</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>11</td>
<td>19</td>
<td>2.605</td>
<td>0.475–14.299</td>
<td/></tr>
<tr>
<td> • High</td>
<td>11</td>
<td>0</td>
<td/>
<td/>
<td/></tr>
<tr>
<td>Left vertebral artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>1</td>
<td>11</td>
<td/>
<td/>
<td><bold>0.001</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>16</td>
<td>15</td>
<td>11.733</td>
<td>1.347–102.243</td>
<td/></tr>
<tr>
<td> • High</td>
<td>7</td>
<td>2</td>
<td>38.5</td>
<td>2.915–508.463</td>
<td/></tr>
<tr>
<td>Basilar artery</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> • Low</td>
<td>1</td>
<td>7</td>
<td/>
<td/>
<td><bold>0.024</bold><bold><xref ref-type="table-fn" rid="table-fn2-0961203312436853">*</xref></bold></td></tr>
<tr>
<td> • Normal</td>
<td>14</td>
<td>13</td>
<td>7.539</td>
<td>0.812–69.906</td>
<td/></tr>
<tr>
<td> • High</td>
<td>8</td>
<td>4</td>
<td>14</td>
<td>1.252–156.610</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312436853"><label>*</label><p>Chi-square test for linear trend.</p></fn>
<fn id="table-fn3-0961203312436853"><p>PAPS: primary antiphospholipid syndrome.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0961203312436853" position="float"><label>Table 4</label><caption><p>Flow comparison in cerebral arteries between PAPS cases and controls</p></caption>
<graphic alternate-form-of="table4-0961203312436853" xlink:href="10.1177_0961203312436853-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Group</th>
<th colspan="4">Cases<hr/></th>
<th colspan="4">Controls<hr/></th>
<th rowspan="2"><italic>P</italic><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></th></tr>
<tr><th><italic>N</italic></th>
<th>MFV</th>
<th>Median</th>
<th>SD</th>
<th><italic>N</italic></th>
<th>MFV</th>
<th>SD</th>
<th>Median</th></tr></thead>
<tbody align="left">
<tr>
<td>RCS</td>
<td>24</td>
<td>50.83</td>
<td>45.5</td>
<td>18.69</td>
<td>28</td>
<td>43.39</td>
<td>8.59</td>
<td>43</td>
<td>0.065</td></tr>
<tr>
<td>LCS</td>
<td>24</td>
<td>53.46</td>
<td>50</td>
<td>23.40</td>
<td>28</td>
<td>44.25</td>
<td>10.02</td>
<td>41.5</td>
<td>0.064</td></tr>
<tr>
<td>RMCA</td>
<td>27</td>
<td>69.22</td>
<td>65</td>
<td>19.66</td>
<td>28</td>
<td>55.25</td>
<td>12.08</td>
<td>54.5</td>
<td><bold>0.002</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
<tr>
<td>LMCA</td>
<td>28</td>
<td>67.96</td>
<td>59.5</td>
<td>23.24</td>
<td>28</td>
<td>60.82</td>
<td>13.11</td>
<td>61</td>
<td>0.162</td></tr>
<tr>
<td>RACA</td>
<td>27</td>
<td>62.11</td>
<td>56</td>
<td>23.08</td>
<td>27</td>
<td>46.22</td>
<td>9.87</td>
<td>44</td>
<td><bold>0.002</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
<tr>
<td>LACA</td>
<td>27</td>
<td>61.96</td>
<td>57</td>
<td>22.46</td>
<td>28</td>
<td>48.68</td>
<td>10.57</td>
<td>49.5</td>
<td>0.007</td></tr>
<tr>
<td>RPCA</td>
<td>27</td>
<td>48.37</td>
<td>45</td>
<td>17.23</td>
<td>28</td>
<td>35.82</td>
<td>7.80</td>
<td>33</td>
<td><bold>0.001</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
<tr>
<td>LPCA</td>
<td>27</td>
<td>45.15</td>
<td>44</td>
<td>14.34</td>
<td>27</td>
<td>37.89</td>
<td>8.52</td>
<td>37</td>
<td><bold>0.028</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
<tr>
<td>RVA</td>
<td>24</td>
<td>43.63</td>
<td>43</td>
<td>13.09</td>
<td>28</td>
<td>31.82</td>
<td>7.79</td>
<td>32.5</td>
<td><bold>0.000</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
<tr>
<td>LVA</td>
<td>24</td>
<td>40.58</td>
<td>38</td>
<td>13.14</td>
<td>28</td>
<td>31.32</td>
<td>9.95</td>
<td>30</td>
<td>0.006</td></tr>
<tr>
<td>BA</td>
<td>24</td>
<td>45.35</td>
<td>44</td>
<td>15.84</td>
<td>28</td>
<td>34.36</td>
<td>8.94</td>
<td>35</td>
<td><bold>0.003</bold><bold><xref ref-type="table-fn" rid="table-fn4-0961203312436853">*</xref></bold></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312436853"><label>*</label><p>: P value statistically significant.</p></fn>
<fn id="table-fn5-0961203312436853"><p>BA: basilar artery; LACA: left anterior cerebral artery; LCS: left carotid siphon; LMCA: left middle cerebral artery; LPCA: left posterior cerebral artery; LVA: left vertebral artery; MFV: mean flow velocity cm/s; RACA: right anterior cerebral artery; RCS: right carotid siphon; RMCA: right middle cerebral artery; RPCA: right posterior cerebral artery; RVA: right vertebral artery; SD: standard deviation.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec7-0961203312436853" sec-type="discussion"><title>Discussion</title>
<p>In this study, PAPS patients without ongoing neurological manifestations had a significant increase of MFV in the MCA, and the other cerebral arteries, indicating an increase in the vascular resistance in PAPS patients in comparison with controls. These results were not associated with carotid IMT, number of involved arteries, transthoracic echocardiography, or arterial hypertension. In addition, there was an increase of mean PI in LPCA and BA. Of interest, patients with five or more arteries with abnormal MFV had a history of stroke, were obese, and were under 50 years of age. A prevalent vascular right involvement was also detected. We found an association between the presence of LA and abnormal TCD, however we did not find association with IgG, IgM aCL and IgG anti-β2GP1.</p>
<p>TCD is not the gold standard method to assess cerebral vascular disease, but it is a noninvasive and very useful method in several entities, such as occlusive disease, angiographic vasospasm, vasomotor reactivity, and cerebral circulatory arrest/ brain death, with strong association with cerebral angiography, the gold standard.<sup><xref ref-type="bibr" rid="bibr13-0961203312436853">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203312436853">14</xref></sup> High grade local stenosis can be found associated with increases or decreases in flow velocity. On the contrary, a milder and more generalized increased flow velocity could reflect cerebral atherosclerosis or arterial narrowing in response to systemic hypertension. In this respect, an association between increase of the MCA flow velocity measured by TCD and the risk of stroke in the general population has been found.<sup><xref ref-type="bibr" rid="bibr15-0961203312436853">15</xref></sup> In relation with PI there were differences in patients and controls only in two segments, PI greater than 1.19 may be caused by a distal occlusion or arterial constriction with high intracranial pressure, however, since PI was within the normal range, these causes were ruled out.<sup><xref ref-type="bibr" rid="bibr12-0961203312436853">12</xref></sup></p>
<p>In our study, the diffuse significant increase of MFV suggests three possibilities: atherosclerosis, APS vasculopathy or both. Different studies indicate the presence of accelerated atherosclerosis in PAPS, similar to that described in other autoimmune rheumatic diseases.<sup><xref ref-type="bibr" rid="bibr16-0961203312436853">16</xref></sup> In fact, an early study described significant carotid IMT in PAPS suggesting that these patients had accelerated atherosclerosis. Patients with IMT had a threefold higher risk for stroke than those without IMT.<sup><xref ref-type="bibr" rid="bibr17-0961203312436853">17</xref></sup> A recent meta-analysis confirmed the presence of accelerated atherosclerosis measuring carotid IMT as a surrogate for premature atherosclerosis in rheumatic diseases, including PAPS.<sup><xref ref-type="bibr" rid="bibr18-0961203312436853">18</xref></sup> In this regard, the MFV &gt; 100 cm/s corresponded well with a MCA stenosis of 50%.<sup><xref ref-type="bibr" rid="bibr19-0961203312436853">19</xref></sup> On the contrary, Bos et al.<sup><xref ref-type="bibr" rid="bibr15-0961203312436853">15</xref></sup> found that high MFV but &lt;100 cm/s in senile patients with a mean age of 70 years, corresponded to a more generalized arterial narrowing caused by atherosclerosis and this finding may be a risk factor for stroke. In the present study, the majority of our patients with a mean age of 41 years, had high MFV but less than 100 cm/s without association with carotid IMT. In consequence, the increase of MFV in PAPS patients could be the reflection of brain accelerated atherosclerosis and/or APS vasculopathy, which could be risk factors for stroke. Interestingly, a 32-year-old patient, had a very high MFV in the MCA, 131 cm/s (normal value: 57 ± 11.2) and she developed an ischemic stroke 2 months after performance of TCD. On the other hand our PAPS patients exhibited a higher prevalence of risk factors for atherosclerosis, such as systemic hypertension, obesity and dyslipidemia, thus making it difficult to know if cerebral blood flow abnormalities are due to atherosclerosis, APS vasculopathy, or both.</p>
<p>A finding of our study was a predominant right hemispheric affection, although we do not have an explanation for this. It is noteworthy that in sickle cell anemia, there are MFV differences between both cerebral hemispheres.<sup><xref ref-type="bibr" rid="bibr20-0961203312436853">20</xref></sup> In relation to the lack of correlation between IMT and MFV, the atherosclerosis process may differ in the intracranial and extracranial arteries, due to histological differences. Extracranial arteries and lower extremity arteries are elastic vessels that are rich in elastic fibers, while intracranial arteries are muscular vessels with smaller amounts of elastic fibers concentrated inside the internal elastic lamina.<sup><xref ref-type="bibr" rid="bibr21-0961203312436853">21</xref></sup> Therefore different mechanisms may produce atherosclerosis in the extracranial and intracranial arteries.<sup><xref ref-type="bibr" rid="bibr22-0961203312436853">22</xref></sup> The importance of intracranial atherosclerosis, if present, is that it may be a marker of cerebrovascular and systemic atherosclerosis somewhere else. Moreover there may be ethnic differences, since it is more severe in black, Asian and oriental people and may have a worse prognosis than extracranial disease.<sup><xref ref-type="bibr" rid="bibr23-0961203312436853">23</xref></sup></p>
<p>Padovan et al.<sup><xref ref-type="bibr" rid="bibr24-0961203312436853">24</xref></sup> analyzed the factors and comorbidities potentially related to central nervous system involvement in SLE patients. aPL, LA, APS, among others, were more frequently detected in neuro-psychiatric SLE patients than in controls. Other studies have shown robust associations between aPL or LA and the incidence of ischemic strokes in young adults.<sup><xref ref-type="bibr" rid="bibr25-0961203312436853">25</xref></sup> A recent prospective study of 1047 recently diagnosed SLE patients, demonstrated that LA at baseline, was associated with an increased future risk of intracranial thrombosis.<sup><xref ref-type="bibr" rid="bibr26-0961203312436853">26</xref></sup> In our population, an association between the presence of LA and abnormal TCD was found, suggesting that this antibody may contribute not only to the pathogenesis of ischemic or thrombotic brain diseases but to the development of other mechanisms affecting cerebral blood flow in PAPS patients.</p>
<p>There is evidence to suggest that the presence of a vasculopathy in APS may lead to arterial stenotic lesions, possibly contributing to vascular occlusions.<sup><xref ref-type="bibr" rid="bibr3-0961203312436853">3</xref></sup> Patients with SLE and associated APS had arterial angiograms with gradual narrowing of the arterial lumen with striking intimal and medial proliferation as well as an increase in thickness of the adventitia.<sup><xref ref-type="bibr" rid="bibr27-0961203312436853">27</xref></sup> An autopsy study in SLE patients with aCL showed frequent occlusive vascular changes such as thromboses, thrombotic microangiopathy related changes and arterial intimal fibrous hyperplasia.<sup><xref ref-type="bibr" rid="bibr28-0961203312436853">28</xref></sup> Few studies have reviewed the cerebral vasculopathy in PAPS. Siqueira Neto et al.<sup><xref ref-type="bibr" rid="bibr29-0961203312436853">29</xref></sup> reported two cases of young patients with cerebral infarct and PAPS. In one case, angiographic findings were similar to ‘vasculitis’ in intracranial vessels. In the other case, obstruction in the internal carotid artery was observed suggesting thrombosis in situ; at necropsy of one of them, non-atherosclerotic obstruction in coronary arteries was found. In catastrophic APS, thrombotic microangiopathy is a characteristic of the CNS pathology and should be considered a potential cause of death.<sup><xref ref-type="bibr" rid="bibr30-0961203312436853">30</xref></sup> All these necropsy studies illustrate the existence of indubitable vasculopathy in PAPS patients.</p>
<p>Previous studies using TCD in order to detect microembolic signals, found that APS patients (the majority with SLE) had cerebral microemboli, correlating with a history of cerebrovascular ischemia and SLE activity.<sup><xref ref-type="bibr" rid="bibr8-0961203312436853">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203312436853">9</xref></sup> Another study in SLE patients, revealed a decrease in the cerebral circulation as well as flow asymmetry in patients with associated APS compared with those without APS. Unfortunately, in our study, we did not detect microemboli, due to the characteristics of the ultrasonography equipment. Cerebral blood flow has been examined in primary and associated APS patients using other methods such as brain single photon emission computed tomography with the finding of hypoperfusion lesions; and yet, these studies were performed in patients with neuropsychiatric manifestations, including headache.<sup><xref ref-type="bibr" rid="bibr6-0961203312436853">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203312436853">7</xref>,<xref ref-type="bibr" rid="bibr31-0961203312436853">31</xref>,<xref ref-type="bibr" rid="bibr32-0961203312436853">32</xref></sup> Because migraine, a clinical manifestation of APS, is considered a vasomotor disorder manifested during attacks with a significant decrease in intracranial blood flow velocity, we did not include patients with migraine attacks. In addition, the number of patients with a history of migraine was scarce.<sup><xref ref-type="bibr" rid="bibr33-0961203312436853">33</xref></sup></p>
<p>Novel neuroimaging studies utilizing volumetric assessments, magnetization transfer imaging and diffusion weighted imaging reveal that non-CNS PAPS patients have subclinical cerebral damage with microstructural changes even in patients without previous CNS events.<sup><xref ref-type="bibr" rid="bibr25-0961203312436853">25</xref>,<xref ref-type="bibr" rid="bibr34-0961203312436853">34</xref></sup> However these studies are not amply suitable. Therefore, according to our experience, TCD confers useful information and it is more widely available. The strength of our study is that it was performed in PAPS patients without ongoing neurological manifestations exclusively, suggesting subclinical vascular damage. The weakness of our study is the small sample size and the study design.</p>
<p>Early detection of CBF abnormalities in asymptomatic PAPS patients, allows taking optimal treatment strategies to protect against irreversible brain injuries. In this regard, experimental and clinical studies have identified both vaso- and cerebro-protective effects of statin treatment in various conditions including patients with high vascular risk, therefore it could be a therapeutic option in PAPS patients,<sup><xref ref-type="bibr" rid="bibr35-0961203312436853">35</xref></sup> together with a strict control of traditional risk factors for atherosclerosis, as well as close monitoring of anticoagulant levels. Recent trials have shown that angiotensin AT1-receptor blockers may confer cerebrovascular protection by favoring cerebral blood flow (angiogenesis and recruitment of pre-existing collateral circulation, specifically in the ischemic brain where AT2 receptors are over-expressed, thus it could be another possible treatment in these patients.<sup><xref ref-type="bibr" rid="bibr36-0961203312436853">36</xref></sup> Finally, for the likely implications of TCD findings, this should be performed periodically in PAPS patients.</p>
<p>In conclusion: asymptomatic patients with PAPS can have significantly increased MFVs. These alterations were observed in patients below 50 years of age, without correlation with carotid IMT. The abnormal increase in CBF seems to be the consequence of PAPS brain atherosclerosis, and/or vasculopathy. Whatever the cause, these findings can represent a risk for stroke in PAPS patients that need the trial of other therapeutic options.</p></sec>
</body>
<back>
<sec id="sec8-0961203312436853"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<sec id="sec9-0961203312436853"><title>Conflict of interest</title>
<p>None declared.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312436853"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>D</given-names></name><name><surname>Erkan</surname><given-names>D</given-names></name></person-group>. <article-title>Antiphospholipid syndrome</article-title>. <source>Prog Cardiovasc Dis</source> <year>2009</year>; <volume>52</volume>: <fpage>115</fpage>–<lpage>125</lpage>.</citation></ref>
<ref id="bibr2-0961203312436853"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanna</surname><given-names>G</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name></person-group>. <article-title>Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology</article-title>. <source>Ann N Y Acad Sci</source> <year>2005</year>; <volume>1051</volume>: <fpage>465</fpage>–<lpage>486</lpage>.</citation></ref>
<ref id="bibr3-0961203312436853"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christodoulou</surname><given-names>C</given-names></name><name><surname>Sangle</surname><given-names>S</given-names></name><name><surname>D'Cruz</surname><given-names>DP</given-names></name></person-group>. <article-title>Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome</article-title>. <source>Rheumatology (Oxford)</source> <year>2007</year>; <volume>46</volume>: <fpage>907</fpage>–<lpage>910</lpage>.</citation></ref>
<ref id="bibr4-0961203312436853"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westerman</surname><given-names>EM</given-names></name><name><surname>Miles</surname><given-names>JM</given-names></name><name><surname>Backonja</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>1038</fpage>–<lpage>1041</lpage>.</citation></ref>
<ref id="bibr5-0961203312436853"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>A</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name></person-group>. <article-title>Hypoperfusion of brain single photon emission computerized tomography in patients with antiphospholipid antibodies</article-title>. <source>J Dermatol Sci</source> <year>1997</year>; <volume>14</volume>: <fpage>20</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr6-0961203312436853"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Shiau</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Abnormal regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with normal magnetic resonance imaging findings</article-title>. <source>A preliminary report. <italic>Scand J Rheumatol</italic></source> <year>2002</year>; <volume>31</volume>: <fpage>89</fpage>–<lpage>93</lpage>.</citation></ref>
<ref id="bibr7-0961203312436853"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elubaeva</surname><given-names>VI</given-names></name><name><surname>Mach</surname><given-names>ES</given-names></name><name><surname>Reshetniak</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>The cerebral blood circulation in patients with systemic lupus erythematosus and the antiphospholipid syndrome</article-title>. <source>Ter Arkh</source> <year>1994</year>; <volume>66</volume>: <fpage>16</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr8-0961203312436853"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Specker</surname><given-names>C</given-names></name><name><surname>Rademacher</surname><given-names>J</given-names></name><name><surname>Söhngen</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Cerebral microemboli in patients with antiphospholipid syndrome</article-title>. <source>Lupus</source> <year>1997</year>; <volume>6</volume>: <fpage>638</fpage>–<lpage>644</lpage>.</citation></ref>
<ref id="bibr9-0961203312436853"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rademacher</surname><given-names>J</given-names></name><name><surname>Sohngen</surname><given-names>D</given-names></name><name><surname>Specker</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?</article-title> <source>Acta Neurol Scand</source> <year>1999</year>; <volume>99</volume>: <fpage>356</fpage>–<lpage>361</lpage>.</citation></ref>
<ref id="bibr10-0961203312436853"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr11-0961203312436853"><label>11</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Moltó</surname><given-names>JM</given-names></name></person-group>. <article-title>Localización de los principales vasos mediante Doppler transcraneal</article-title>. In: <person-group person-group-type="editor"><name><surname>Molina</surname><given-names>C</given-names></name><name><surname>Serena</surname><given-names>J</given-names></name><name><surname>Alvarez Sabín</surname><given-names>J</given-names></name></person-group> (eds). <source>Manual de Doppler transcraneal</source>. <publisher-loc>Madrid, Spain</publisher-loc>: <publisher-name>Aula Médica Ediciones</publisher-name>, <year>2000</year>; <fpage>33</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr12-0961203312436853"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicoletto</surname><given-names>HA</given-names></name><name><surname>Burkman</surname><given-names>MH</given-names></name></person-group>. <article-title>Transcranial Doppler series part III: interpretation</article-title>. <source>Am J Electroneurodiagnostic Technol</source> <year>2009</year>; <volume>49</volume>: <fpage>244</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr13-0961203312436853"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rorick</surname><given-names>MB</given-names></name><name><surname>Nichols</surname><given-names>FT</given-names></name><name><surname>Adams</surname><given-names>RJ</given-names></name></person-group>. <article-title>Transcranial Doppler correlation with angiography in detection of intracranial stenosis</article-title>. <source>Stroke</source> <year>1994</year>; <volume>25</volume>: <fpage>1931</fpage>–<lpage>1934</lpage>.</citation></ref>
<ref id="bibr14-0961203312436853"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>MA</given-names></name><name><surname>Alexandrov</surname><given-names>AV</given-names></name><name><surname>Tegeler</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</article-title>. <source>Neurology</source> <year>2004</year>; <volume>62</volume>: <fpage>1468</fpage>–<lpage>1481</lpage>.</citation></ref>
<ref id="bibr15-0961203312436853"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>MJ</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Transcranial Doppler hemodynamic parameters and risk of stroke: the Rotterdam study</article-title>. <source>Stroke</source> <year>2007</year>; <volume>9</volume>: <fpage>2453</fpage>–<lpage>2458</lpage>.</citation></ref>
<ref id="bibr16-0961203312436853"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Gerli</surname><given-names>R</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Accelerated atherosclerosis in autoimmune rheumatic diseases</article-title>. <source>Circulation</source> <year>2005</year>; <volume>21</volume>: <fpage>3337</fpage>–<lpage>3347</lpage>.</citation></ref>
<ref id="bibr17-0961203312436853"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>G</given-names></name><name><surname>Casaos</surname><given-names>D</given-names></name><name><surname>Jara</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome</article-title>. <source>Ann Rheum Dis</source> <year>2003</year>; <volume>62</volume>: <fpage>607</fpage>–<lpage>610</lpage>.</citation></ref>
<ref id="bibr18-0961203312436853"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyrrell</surname><given-names>PN</given-names></name><name><surname>Beyene</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2010</year>; <volume>30</volume>: <fpage>1014</fpage>–<lpage>1026</lpage>.</citation></ref>
<ref id="bibr19-0961203312436853"><label>19</label><citation citation-type="journal"><collab>Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) Trial Investigators</collab>. <article-title>Stroke outcome and neuroimaging of intracranial atherosclerosis (SONIA): design of a prospective, multicenter trial of diagnostic tests</article-title>. <source>Neuroepidemiology</source> <year>2004</year>; <volume>23</volume>: <fpage>23</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr20-0961203312436853"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krejza</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Romanowicz</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Sickle cell disease and transcranial Doppler imaging: inter-hemispheric differences in blood flow Doppler parameters</article-title>. <source>Stroke</source> <year>2011</year>; <volume>42</volume>: <fpage>81</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr21-0961203312436853"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Iguchi</surname><given-names>Y</given-names></name><name><surname>Shibazaki</surname><given-names>K</given-names></name><name><surname>Urabe</surname><given-names>T</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name></person-group>. <article-title>Peripheral arterial atherosclerosis in patients with extracranial, not intracranial, arterial stenosis</article-title>. <source>Intern Med</source> <year>2010</year>; <volume>49</volume>: <fpage>1515</fpage>–<lpage>1519</lpage>.</citation></ref>
<ref id="bibr22-0961203312436853"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>T</given-names></name><name><surname>Tabuchi</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>E</given-names></name></person-group>. <article-title>Risk factors for occlusive lesions of intracranial arteries in stroke-free Japanese</article-title>. <source>Eur J Neurol</source> <year>2005</year>; <volume>12</volume>: <fpage>218</fpage>–<lpage>222</lpage>.</citation></ref>
<ref id="bibr23-0961203312436853"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lammie</surname><given-names>GA</given-names></name><name><surname>Sandercock</surname><given-names>PA</given-names></name><name><surname>Dennis</surname><given-names>MS</given-names></name></person-group>. <article-title>Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque</article-title>. <source>Stroke</source> <year>1999</year>; <volume>30</volume>: <fpage>1319</fpage>–<lpage>1325</lpage>.</citation></ref>
<ref id="bibr24-0961203312436853"><label>24</label><citation citation-type="other"><comment>Padovan M, Castellino G, Bortoluzzi A, Caniatti L, Trotta F, Govoni M. Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center. <italic>Rheumatol Int</italic> 2012; 32: 129–135</comment>.</citation></ref>
<ref id="bibr25-0961203312436853"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muscal</surname><given-names>E</given-names></name><name><surname>Brey</surname><given-names>RL</given-names></name></person-group>. <article-title>Antiphospholipid syndrome and the brain in pediatric and adult patients</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>406</fpage>–<lpage>411</lpage>.</citation></ref>
<ref id="bibr26-0961203312436853"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>1726</fpage>–<lpage>1732</lpage>.</citation></ref>
<ref id="bibr27-0961203312436853"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alarcón-Segovia</surname><given-names>D</given-names></name><name><surname>Cardiel</surname><given-names>MH</given-names></name><name><surname>Reyes</surname><given-names>E</given-names></name></person-group>. <article-title>Antiphospholipid arterial vasculopathy</article-title>. <source>J Rheumatol</source> <year>1989</year>; <volume>16</volume>: <fpage>762</fpage>–<lpage>767</lpage>.</citation></ref>
<ref id="bibr28-0961203312436853"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sipek-Dolnicar</surname><given-names>A</given-names></name><name><surname>Hojnik</surname><given-names>M</given-names></name><name><surname>Bozic</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies</article-title>. <source>Clin Exp Rheumatol</source> <year>2002</year>; <volume>20</volume>: <fpage>335</fpage>–<lpage>342</lpage>.</citation></ref>
<ref id="bibr29-0961203312436853"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siqueira Neto</surname><given-names>JI</given-names></name><name><surname>Santos</surname><given-names>AC</given-names></name><name><surname>Fábio</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Cerebral vasculopathy in the primary antiphospholipid antibody syndrome. Report of 2 cases</article-title>. <source>Arq Neuropsiquiatr</source> <year>1996</year>; <volume>54</volume>: <fpage>661</fpage>–<lpage>664</lpage>.</citation></ref>
<ref id="bibr30-0961203312436853"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olguín-Ortega</surname><given-names>L</given-names></name><name><surname>Jara</surname><given-names>LJ</given-names></name><name><surname>Becerra</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neurological involvement as a poor prognostic factor in catastrophic antiphospholipid syndrome: autopsy findings in 12 cases</article-title>. <source>Lupus</source> <year>2003</year>; <volume>12</volume>: <fpage>93</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr31-0961203312436853"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>FY</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report</article-title>. <source>Rheumatol Int</source> <year>2003</year>; <volume>23</volume>: <fpage>301</fpage>–<lpage>304</lpage>.</citation></ref>
<ref id="bibr32-0961203312436853"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Ohta</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Abnormal cerebral blood flow associated with antiphospholipid antibody syndrome–four case reports</article-title>. <source>Neurol Med Chir (Tokyo)</source> <year>1997</year>; <volume>37</volume>: <fpage>41</fpage>–<lpage>48</lpage>.</citation></ref>
<ref id="bibr33-0961203312436853"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomaides</surname><given-names>T</given-names></name><name><surname>Karagounakis</surname><given-names>D</given-names></name><name><surname>Spantideas</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan</article-title>. <source>Headache</source> <year>2003</year>; <volume>43</volume>: <fpage>54</fpage>–<lpage>58</lpage>.</citation></ref>
<ref id="bibr34-0961203312436853"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliveira de Andrade</surname><given-names>DC</given-names></name><name><surname>Borba</surname><given-names>EF</given-names></name><name><surname>Bonfa</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: the role of magnetization transfer imaging</article-title>. <source>J Magn Reson Imaging</source> <year>2008</year>; <volume>27</volume>: <fpage>483</fpage>–<lpage>488</lpage>.</citation></ref>
<ref id="bibr35-0961203312436853"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>V</given-names></name><name><surname>Endres</surname><given-names>M</given-names></name></person-group>. <article-title>The acute (cerebro)vascular effects of statins</article-title>. <source>Anesth Analg</source> <year>2009</year>; <volume>109</volume>: <fpage>572</fpage>–<lpage>584</lpage>.</citation></ref>
<ref id="bibr36-0961203312436853"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oprisiu-Fournier</surname><given-names>R</given-names></name><name><surname>Faure</surname><given-names>S</given-names></name><name><surname>Mazouz</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?</article-title> <source>Expert Rev Neurother</source> <year>2009</year>; <volume>9</volume>: <fpage>1289</fpage>–<lpage>1305</lpage>.</citation></ref>
</ref-list>
</back>
</article>